此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

2026年5月11日 更新者:Memorial Sloan Kettering Cancer Center

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies

The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

研究概览

研究类型

介入性

注册 (估计的)

71

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Andromachi Scaradavou, MD
  • 电话号码:833-MSK-KIDS
  • 邮箱:ScaradaA@mskcc.org

研究联系人备份

  • 姓名:Jaap Jan Boelens, MD, PhD
  • 电话号码:833-MSK-KIDS
  • 邮箱:boelensj@mskcc.org

学习地点

    • New York
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • 接触:
          • Andromachi Scaradavou, MD
          • 电话号码:1-833-MSK-KIDS

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

A patient cannot be considered eligible for this study unless ALL of the following conditions are met.

° Disease type

Cohort 1, High Risk Disease: Patients with age ≤ 26 years at the time of informed consent with no available and suitably matched related or unrelated donor within 4 weeks, with one of the following diagnoses:

I. Acute myelogenous leukemia (AML):

  • Complete first remission (CR1) with blast count < 5% by bone marrow morphology at high risk for relapse such as any of the following:

    • Known prior diagnosis of myelodysplasia (MDS)
    • High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and/or high-risk molecular abnormalities (e.g., TP53)
    • Requirement for 2 or more inductions to achieve CR1
    • Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other malignancy, and/or gene therapy or cell therapy)
    • Presence of Minimal/Measurable Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods (at End of Induction or End of Consolidation)
    • Other high-risk features not defined above.
  • Complete second remission (CR2) or subsequent remission, with blast count < 5% by bone marrow morphology
  • Presence of MRD by multiparameter flow cytometry at pre-transplant evaluation is acceptable.

II. Acute lymphoblastic leukemia (ALL):

  • Complete first remission (CR1) with MRD negative status by multicolor flow cytometry, at high risk for relapse such as any of the following:

    • Presence of any high risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other, KMT2A (11q23) or other high risk molecular abnormality
    • Failure to achieve complete remission (CR) after four weeks of induction therapy (transplant to follow antibody therapy and/or CAR T cells)
    • Persistence or recurrence of MRD on therapy (Transplant to follow antibody therapy and/or CAR T cells)
    • T-ALL in CR even with presence of MRD
    • Other high-risk features not defined above
  • Complete second remission (CR2) or subsequent remission with MRD negative status by multiparameter flow cytometry.

    • Relapse in less than 36 months from CR1
    • Relapse for T-ALL
  • Patients after antibody therapy (e.g., blinatumomab, inotuzumab, other) and/or CAR-T cell therapy that resulted in MRD negative status by multiparameter flow cytometry.

III. Other acute leukemias:

  • Leukemias of ambiguous lineage or of other types with < 5% blasts by bone marrow morphology.
  • Patients with persistent/relapsed disease with cytogenetic, flow cytometric or molecular aberrations in < 5% of cells.
  • Chronic myelogenous leukemia: Patients with history of blast crisis or accelerated phase.
  • Any leukemia that developed after gene therapy or cell therapy

IV. Myelodysplastic Syndrome (MDS):

  • Any IPSS risk category with life-threatening cytopenia(s).
  • Any IPSS risk category with high risk cytogenetic/molecular findings (5, 7, 8, complex karyotype, or TP53)

V. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high risk of relapse or progression if not in remission:

  • Patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell NHL) in CR.
  • Patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/ CR/ PR with no single lesion equal to or more than 5 cm.
  • Patients with HL without progression of disease (POD) after salvage chemotherapy with no single lesion ≥5 cm.

Cohort 2: Very High-Risk disease:

  1. Patients in CR (bone marrow blasts <5% by morphology) who had prior allogeneic transplant and disease recurrence. The second transplant will take place at least 4 months after the first.

    • Acute myelogenous leukemia (AML) or Myelodysplastic Syndrome (MDS): Relapse after previous transplant, in CR after induction therapy. MRD positive status by multi-parameter flow cytometry is accepted.
    • Acute lymphoblastic leukemia (ALL): Relapse after previous transplant, in CR after induction therapy and/or antibody therapy/CAR T cells. MRD positive status after targeted therapy, as evaluated by multi-parameter flow cytometry is accepted.
    • Other: patients with leukemia or lymphoma, who, in the opinion of their physician, are not likely to have reduction in disease burden with further chemotherapy.
  2. Patients with relapsed/refractory disease at either first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology. ° Relapse after previous transplant with < 30% blasts by bone marrow morphology, or with cytogenetic, flow cytometric, or molecular abnormalities in < 30% of bone marrow cells, after induction therapy.

    ° Primary refractory or relapsed AML with < 30% blasts by bone marrow morphology or with cytogenetic, flow cytometric, or molecular abnormalities in < 30% of bone marrow cells.

    ° Age 0-26 years at the time of informed consent

    ° Performance: Karnofsky (≥16 years) or Lansky score (<16 years) of ≥70% (see Appendix A).

    ° Not Pregnant and Not Nursing

    ° Required Organ Function

    • Bilirubin ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia).
    • ALT ≤ 3 x upper limit of normal.
    • Pulmonary function (FVC, FEV1 and DLCO corrected for hemoglobin) ≥ 50% predicted.

      • In young children unable to perform pulmonary function testing: pulse oximetry >92% in room air, and a normal CT of the chest (if CT is not normal, the child needs to be evaluated and cleared by pediatric pulmonary physician).
    • Left ventricular ejection fraction > 50%.
    • Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) ≤ 7.
    • Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of enrolment and must be willing to use an effective contraceptive method while enrolled in the study.
    • Renal: Serum creatinine (SCr) ≤ 1.5 x normal for age. If SCr is outside the normal range, then CrCl > 50 mL/min (calculated or estimated) or estimated GFR (mL/min/1.73m2) >30% of predicted normal for age.

    Normal GFR by Age : Mean GFR +- SD (mL/min/1.73m^2) 1 week : 40.6 + / - 14.8 2-8 weeks : 65.8 + / - 24.8 >8 weeks : 95.7 + / - 21.7 2-12 years : 133.0 + / - 27.0 13-21 years (males) : 140.0 + / - 30.0 13-21 years (females) : 126.0 + / - 22.0

    GFR, glomerular filtration rate; SD, standard deviation; Greater than 2 years old: Normal GFR is 100 mL/ min; Infants: GFR must be corrected for body surface area.

    Exclusion Criteria:

    Exclusion criteria for both cohorts:

    ° Inadequate performance status/ organ function.

    ° Active CNS leukemic involvement.

    • Chloroma >2 cm.
    • Active and uncontrolled infection (bacterial/fungal/viral) at time of transplant.
    • HIV infection.
    • Seropositivity for HTLV-1.
    • Pregnancy or breast feeding.
    • Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.
    • Any abnormal condition or lab result that is considered by the PI capable or altering patient's condition or study outcome.

    Cohort 2 Very High-Risk Disease (additional to above):

    ° Allogeneic HCT in the preceding 4 months.

    Note (1): Prior checkpoint inhibitors/blockade in the last 12 months: eligibility to be discussed with study PI.

    Note (2): For patients with known HBV and/or HCV infection :

    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1: Patients with High-Risk Disease

Participants in complete remission (CR; bone marrow blasts <5% by morphology) with no prior allogeneic transplant, who require allogeneic transplantation and do not have human leukocyte antigen (HLA)-matched related or unrelated donors readily available within 4 weeks.

For participants with AML/MDS, MRD (Measurable/Minimal Residual Disease) positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry); participants with ALL need to be in MRD negative status (evaluated by multiparameter flow cytometry).

Cord Blood [(HPC(CB)] products are minimally manipulated unrelated allogeneic cord blood units that have been collected, processed and stored in public Cord Blood banks
Hyper-fractionated TBI is administered by a linear accelerator at a dose rate of <20 cGy/minute. Treatment planning begins with simulation.
其他名称:
  • 脑外伤
Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis.
其他名称:
  • 胞毒素
  • 新星
Fludarabine phosphate is rapidly dephosphorylated to 2- fluoro-ara- A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2- fluoro-ara-ATP
其他名称:
  • 氟达拉
Clofarabine, a purine (deoxyadenosine) nucleoside analog, is metabolized to clofarabine 5'-triphosphate.
其他名称:
  • 衣领
Busulfan is a bifunctional alkylating agent known chemically as 1,4- butanediol, dimethanesulfonate.
其他名称:
  • 白消安
Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.
其他名称:
  • 硫杂
Tacrolimus inhibits T-lymphocyte activation
其他名称:
  • 程序
Mycophenolate exhibits a cytostatic effect on T and B lymphocytes.
其他名称:
  • 细胞概念
Cyclosporine is a calcineurin inhibitor that inhibits production and release of interleukin II and inhibits interleukin II-induced activation of resting T-lymphocytes.
实验性的:Cohort 2: Patients with Very High-Risk Disease
  1. Participants in CR (bone marrow blasts <5% by morphology) who had prior allogeneic transplant and disease recurrence.

    1. Participants with AML/MDS: MRD positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry)
    2. Participants with ALL: MRD positive status at the time of transplant is accepted (evaluated by multiparameter flow cytometry).
    3. The second transplant will take place at least 4 months after the first.
  2. Participants with relapsed/refractory disease at first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology.
Cord Blood [(HPC(CB)] products are minimally manipulated unrelated allogeneic cord blood units that have been collected, processed and stored in public Cord Blood banks
Hyper-fractionated TBI is administered by a linear accelerator at a dose rate of <20 cGy/minute. Treatment planning begins with simulation.
其他名称:
  • 脑外伤
Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis.
其他名称:
  • 胞毒素
  • 新星
Fludarabine phosphate is rapidly dephosphorylated to 2- fluoro-ara- A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2- fluoro-ara-ATP
其他名称:
  • 氟达拉
Clofarabine, a purine (deoxyadenosine) nucleoside analog, is metabolized to clofarabine 5'-triphosphate.
其他名称:
  • 衣领
Busulfan is a bifunctional alkylating agent known chemically as 1,4- butanediol, dimethanesulfonate.
其他名称:
  • 白消安
Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.
其他名称:
  • 硫杂
Tacrolimus inhibits T-lymphocyte activation
其他名称:
  • 程序
Mycophenolate exhibits a cytostatic effect on T and B lymphocytes.
其他名称:
  • 细胞概念
Cyclosporine is a calcineurin inhibitor that inhibits production and release of interleukin II and inhibits interleukin II-induced activation of resting T-lymphocytes.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Disease-free Survival (DFS)
大体时间:1 year
Disease-free Survival (DFS) at 1 year after CBT
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Andromachi Scaradavou, MD、Memorial Sloan Kettering Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月28日

初级完成 (估计的)

2030年4月28日

研究完成 (估计的)

2030年4月28日

研究注册日期

首次提交

2026年4月29日

首先提交符合 QC 标准的

2026年4月29日

首次发布 (实际的)

2026年5月5日

研究记录更新

最后更新发布 (实际的)

2026年5月14日

上次提交的符合 QC 标准的更新

2026年5月11日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅